Melarsoprol-free drug combinations for second-stage gambian sleeping sickness: The way to go

Clinical Infectious Diseases

Volumn 45, Issue 11, 2007, Pages 1443-1445

  Chappuis, François ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; MELARSOPROL; NIFURTIMOX; PAFURAMIDINE; PENTAMIDINE; ANTITRYPANOSOMAL AGENT;

AFRICAN TRYPANOSOMIASIS; BLEEDING; BRAIN EDEMA; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; ENDEMIC DISEASE; ENTEROCOLITIS; GAMBIA; HEALTH CARE ORGANIZATION; HUMAN; LIVER TOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; NOTE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; DRUG COMBINATION; DRUG RESISTANCE;

DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EFLORNITHINE; GAMBIA; HUMANS; MELARSOPROL; NIFURTIMOX; TRYPANOCIDAL AGENTS; TRYPANOSOMIASIS, AFRICAN;

EID: 38449119914     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/522983     Document Type: Note

References (11)

1. World Health Organization. Human African trypanosomiasis (sleeping sickness): epidemiological update. Wkly Epidemiol Record 2006; 81:71-80.
2. Brun R, Schumacher R, Schmid C, Kunz C, Burri C. The phenomenon of treatment failures in human African Trypanosomiasis. Trop Med Int Health 2001; 6:906-14.
3. Van Nieuwenhove S, Schechter PJ, Declercq J, Bone G, Burke J, Sjoerdsma A. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial. Trans R Soc Trop Med Hyg 1985; 79:692-8.
4. Pepin J, Khonde N, Maiso F, et al. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bull World Health Organ 2000; 78: 1284-95.
5. Chappuis F, Udayraj N, Stietenroth K, Meussen A, Bovier PA. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis 2005; 41: 748-51.
6. Balasegaram M, Harris S, Checchi F, Ghorashian S, Hamel C, Karunakara U. Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo. Bull World Health Organ 2006; 84:783-91.
7. Pepin J, Milord F, Meurice F, Ethier L, Loko L, Mpia B. High-dose nifurtimox for arsenoresistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Trans R Soc Trop Med Hyg 1992; 86:254-6.
8. Bisser S, N'Siesi FX, Lejon V, et al. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J Infect Dis 2007; 195:322-9.
9. Priotto G, Fogg C, Balasegaram M, et al. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials 2006; 1:e39.
10. Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, Priotto G. Nifurtimox plus eflornithine for late-stage Trypanosoma brucei gambiense sleeping sickness in Uganda: a case-series. PloS Neglected Dis (in press).
11. Priotto G, Kasparian S, Ngouama D, et al. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis 2007; 45: 1435-42 (in this issue).